Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

CSTL - CASTLE BIOSCIENCES INC

IEX Last Trade
27.69
-2.570   -9.281%

Share volume: 0
Last Updated: Tue 24 Dec 2024 06:17:49 PM CET

PREVIOUS CLOSE
CHG
CHG%
$30.26
-2.57
-8.49%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Historical prices Events Documents Notes Dividends
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.69%
1 Month
-6.07%
3 Months
-3.08%
6 Months
29.29%
1 Year
28.16%
2 Year
28.57%
Key data
Stock price
$27.69
P/E Ratio 
-264.31
DAY RANGE
$27.33 - $30.26
EPS 
-$0.11
52 WEEK RANGE
$18.29 - $35.84
52 WEEK CHANGE
$25.26
MARKET CAP 
819.105 M
YIELD 
N/A
SHARES OUTSTANDING 
27.607 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
BETA 
1.68
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$251,997
AVERAGE 30 VOLUME 
$299,776
Company detail
CEO: Derek J. Maetzold
Region: US
Website: castlebiosciences.com
Employees: 540
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry:
Sector:

Castle Biosciences, Inc. focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company was founded in 2007 and is headquartered in Friendswood, Texas.

Recent news